Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 1 × Recurrence × axicabtagene ciloleucel × Clear all

Phase

Phase 2 1 Phase 1 1

Status

Active not recruiting 1

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Lymphoma, Non-Hodgkin 3 Lymphoma, Large B-Cell, Diffuse 2 Recurrence 1 Lymphoma 1 HIV Infections 1

Interventions

Cyclophosphamide 39 fludarabine 28 Dexamethasone 23 venetoclax 19 Cytarabine 16 Rituximab 13 pembrolizumab 12 fludarabine phosphate 12 Filgrastim 12 Gemcitabine 10 Etoposide 10 Granulocyte Colony-Stimulating Factor 9 carfilzomib 8 Vincristine 8 Topotecan 8 Lenalidomide 8 Interleukin-2 8 Decitabine 8 pomalidomide 7 Nivolumab 7 Melphalan 7 Everolimus 7 Doxorubicin 7 Calcium Dobesilate 7 Bortezomib 7 Azacitidine 7 Vorinostat 6 Injections 6 Carboplatin 6 obinutuzumab 5

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT04608487 2025-07-30

Axi-cel in CNS Lymphoma

Dana-Farber Cancer Institute

Phase 1 Active not recruiting

Lymphoma, Recurrence

Data powered by HemOnc (CC BY 4.0) Colophon ⚡